Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD 0200390 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 15 mg | EXPERIMENTAL | - |
| 25 mg | EXPERIMENTAL | - |
| 35 mg | EXPERIMENTAL | - |
| 5 mg | EXPERIMENTAL | - |
| 50 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 30 mg | EXPERIMENTAL | - |
| 60 mg | EXPERIMENTAL | - |
| 15 mg PD 0200390 | EXPERIMENTAL | - |
| 30 mg PD 0200390 | EXPERIMENTAL | - |
| 45 mg PD 0200390 | EXPERIMENTAL | - |
| 60 mg PD 0200390 | EXPERIMENTAL | - |
| Placebo PD 0200390 | EXPERIMENTAL | - |
| A425 | EXPERIMENTAL | A425 Treated |
| Name | Type | Description |
|---|---|---|
| PD 0200390 | DRUG | oral 15 mg daily dose, 3 capsules per dose during a six week treatment period. |
| Placebo | DRUG | oral placebo daily dose, 3 capsules per dose during a six week treatment period. |
Inclusion Criteria: * Awake unrestored or unrefreshed, associated with significant distress or impairment in social, occupational, or other important areas of functioning during the daytime, for at least 3 nights for the past 3 months prior to screening * Self-report wake after sleep onset \<45 min...
Top 2 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Vanda Pharmaceuticals Inc. | VNDA | 2 | PHASE3 | tasimelteon |
PD 0200390 is an investigational small molecule being developed for the treatment of insomnia, including primary insomnia and nonrestorative sleep. It is a psychiatry therapeutic that has been studied in Phase 2 clinical trials for these sleep disorders.
PD 0200390 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in clinical development and has not been approved by regulatory authorities.
PD 0200390 is in Phase 2 clinical development. It has completed two Phase 2 trials in adults with primary insomnia and nonrestorative sleep, as well as a Phase 1 study. The drug remains investigational and has not received regulatory approval.
PD 0200390 has completed several clinical trials, including NCT00551148, a dose-ranging polysomnography trial in primary insomnia; NCT00569972, a placebo-controlled outpatient trial in insomnia; and NCT00655369, a trial in nonrestorative sleep. All trials have been completed.
PD 0200390 is also referred to as PD 00200390 in some clinical trial records. For example, NCT00655369, a trial in adults with nonrestorative sleep, uses the name PD 00200390 to describe the same investigational drug.